An Open-Label Study to Assess the Effect of First-Line Treatment With Avastin in Combination With Standard Therapy on Progression-Free Survival in Patients With Metastatic Renal Cell Cancer

Trial Profile

An Open-Label Study to Assess the Effect of First-Line Treatment With Avastin in Combination With Standard Therapy on Progression-Free Survival in Patients With Metastatic Renal Cell Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Nov 2014

At a glance

  • Drugs Bevacizumab (Primary) ; Interferon alpha-2a; Vinblastine
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 31 Mar 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
    • 26 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Mar 2010 Planned number of patients changed from 180 to 25 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top